138 related articles for article (PubMed ID: 20373860)
1. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
Stebbing J; Ellis P; Tutt A
Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
[No Abstract] [Full Text] [Related]
2. An Achilles' heel for breast cancer?
Caldecott KW; Chalmers A
Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
[No Abstract] [Full Text] [Related]
3. PARP inhibitors: will the new class of drugs match the hype?
Tuma RS
J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
[No Abstract] [Full Text] [Related]
4. Development of PARP inhibitors: an unfinished story.
Patel A; Kaufmann SH
Oncology (Williston Park); 2010 Jan; 24(1):66, 68. PubMed ID: 20187324
[No Abstract] [Full Text] [Related]
5. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
6. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors: what we know and what we have yet to know.
Puhalla S
Oncology (Williston Park); 2010 Jan; 24(1):62, 65-6. PubMed ID: 20187323
[No Abstract] [Full Text] [Related]
9. Novel targets for triple-negative breast cancer.
Carey LA
Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
[No Abstract] [Full Text] [Related]
10. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibition in breast cancer.
Garber J
Clin Adv Hematol Oncol; 2009 Sep; 7(9):573-5. PubMed ID: 20020667
[No Abstract] [Full Text] [Related]
13. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
14. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.
Balmaña J; Domchek SM; Tutt A; Garber JE
Cancer Discov; 2011 Jun; 1(1):29-34. PubMed ID: 22586318
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibition and synthetic lethality in ovarian cancer.
Eskander RN; Tewari KS
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):613-22. PubMed ID: 24984781
[TBL] [Abstract][Full Text] [Related]
16. [PARP inhibitors and breast cancer: update and perspectives].
Gonçalves A
Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
[TBL] [Abstract][Full Text] [Related]
17. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
[TBL] [Abstract][Full Text] [Related]
18. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
19. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer.
Domchek SM; Mitchell G; Lindeman GJ; Tung NM; Balmaña J; Isakoff SJ; Schmutzler R; Audeh MW; Loman N; Scott C; Friedlander M; Kaufman B; Garber JE; Tutt A; Robson ME
J Clin Oncol; 2011 Nov; 29(32):4224-6. PubMed ID: 21931031
[No Abstract] [Full Text] [Related]
20. Making the best of PARP inhibitors in ovarian cancer.
Banerjee S; Kaye SB; Ashworth A
Nat Rev Clin Oncol; 2010 Sep; 7(9):508-19. PubMed ID: 20700108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
